Prostan
5 mg № 10, № 30
Pharmacotherapeutic group
Active ingredient
Pharmaceutical form
Film-coated tablets
ATC code
G04CB01
RX/OTC
RX
Registration certificate
UA/8262/01/01
General properties
Pharmacotherapeutic group
Drugs used in benign prostatic hypertrophy.
Therapeutic indications
Treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate to:
- size reduction (regression) of enlarged prostate to improve urine flow and reduce symptoms associated with benign prostatic hyperplasia;
- reduce the risk of acute urinary retention and the need for surgical intervention, including prostate and transuretrorezektsii prostatectomy.
Contraindications
Hypersensitivity to finasteride or to any component of the drug. Prostan is not indicated for use in women and children.
Pharmaceutical characteristics
Main physicochemical properties
Round-shaped tablets, coated tablets, reddish-pink in color, the upper and lower surfaces are convex. At the break when viewed under a microscope can see a core surrounded by one continuous layer.
Shelf life
2 years.
Storage
Keep in original package at temperature not exceeding 30 оС.
Keep out of reach of children
Manufacturer
PJSC "Technolog".
Location
8, Stara Prorizna st., Uman 20300 Cherkasy region, Ukraine.
